Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Net margin-200%-184pp-203.3%-212pp-56.1%+1,856pp-42.7%+8,926pp-16.1%+496,944pp
Returns
Return on equity-136.4%-129pp-92.3%-95.6pp-45.9%-23.5pp-23.6%-6.9%
Return on invested capital-125.5%-85.0pp-95.6%-70.2pp-78.3%-42.5pp-65%-40.4%
Efficiency
Asset turnover0.3×0.0×0.2×-0.1×0.5×+0.5×0.4×+0.4×0.4×
Liquidity
Current ratio4.9×-6.1×7.3×-7.0×6.7×-5.9×6.2×-26.7×11×-49.9×
Leverage
Debt-to-equity1.6×+1.6×0.8×+0.8×0.7×+0.7×0.0×0.0×
Per Share
Book value per share$0.62-73.6%$1.16-53.8%$1.49-27.8%$1.96-12.0%$2.34+0.6%
Valuation
Market capitalization$1.05B-32.6%$1.15B+12.3%$993.2M-29.3%$1.65B+101%$1.23B+25.3%
Price / sales10.6×-5.4×13.7×+2.2×-540×14.7×-1,628×12.7×-98,523×
Price / book17.1×+10.3×10.1×+6.1×6.7×-0.3×8.6×+4.8×5.4×+1.0×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do ARS Pharmaceuticals, Inc.'s ratios come from?
Every ratio is computed from ARS Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.